Navigation Links
Sysmex America Begins Distribution of CellaVision® DM1200
Date:7/20/2010

MUNDELEIN, Ill., July 20 /PRNewswire/ -- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced the addition of the CellaVision® DM1200 cell image analysis analyzer to the Sysmex hematology product offering.  The DM1200 enables Sysmex America to meet the growing demand for automated cell image analysis, which improves both the quality of results and the productivity of laboratories performing mid-volume testing.    

The CellaVision® DM1200 opens up new ways of handling manual differentials traditionally performed on a microscope by automatically performing a preliminary differential count on peripheral blood. The analyzer pre-classifies the white blood cells, pre-characterizes parts of the red morphology and provides functionality for platelet estimation. By automating the manual differential, laboratories can experience enhanced turnaround times without sacrificing quality.  Its high degree of automation allows for an escalating workload without increasing labor.

"The CellaVision DM1200, which locates, identifies, and pre-classifies blood cells by means of automatic microscopy and advanced image processing, greatly enhances Sysmex America's hematology product offering.  We trust this addition to our hematology portfolio will serve our customers well as they continue to navigate through a challenging health care environment," said John Kershaw, President & CEO, Sysmex America, Inc.    

Sysmex America and CellaVision first initiated their working relationship in 2004.  Today, Sysmex Corporation and CellaVision have an extended and broadened working relationship via the completion of a recent global distribution agreement.  The agreement gives Sysmex a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide.  As of April 1, 2010, the non-exclusive agreement comprises all international markets but Canada.  

About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.  The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.  CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems.  Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.  For more information about Sysmex, please visit www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OhioHealth Installs Newest Version of Sysmexs Hematology Middleware, Sysmex WAM(TM) 4.0
2. Sysmex America Adds Industry Veteran to Company Leadership
3. Sysmex America Honored Second Consecutive Year as a Company That Cares
4. Sysmex America Announces Executive Leadership Changes
5. Sysmex America Announces Amerinet Urinalysis Contract
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. Aspirin Named 8th World Wonder by Majority of Americans
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President ... later this year. Dyer started as the Chairman of the Management Committee when ... of the corporation including the recruitment of investor/owners and development of the business plan. ...
Breaking Medicine News(10 mins):